Citation: Ma H-C, Liu Y, Wang C, Strauss M, Rehage N, Chen Y-H, et al
CrossRef The impact of metabolic dysfunction-associated steatotic liver disease on the efficacy of pegylated interferon-based therapy in patients with chronic hepatitis B Jiaxin Han, Lianxin Xu, Yuqin Li, Ziling Wang, Minghui Zeng, Jieru Gao, Yuqiang Mi, Wentao Kuai, Huiling Xiang, Liang Xu Frontiers in Immunology .2026;[Epub] CrossRef Type 2 diabetes as a key metabolic risk factor for adverse outcomes in nucleos(t)ide analogue-treated chronic hepatitis B: Editorial on Impacts of metabolic syndrome diseases on long-term outcomes of chronic hepatitis B patients treated with nucleos(t)id Heejoon Jang, Won Kim Clinical and Molecular Hepatology .2026
Improving metabolic health with tirzepatide helps with weight loss and other metabolic issues
Motley Rice supports a separate vision loss MDL Motley Rice member attorney Jonathan Orent is co-lead counsel for the pre-existing MDL and has been closely involved in shaping the litigation against Novo Nordisk and Eli Lilly
DOI: 10.1016/j.mad.2016.01.002 28